R1	Has_value Arg1:T3 Arg2:T2	
R2	Has_value Arg1:T4 Arg2:T5	
R3	Has_negation Arg1:T8 Arg2:T14	
R4	Has_qualifier Arg1:T8 Arg2:T6	
*	OR T9 T12 T10 T11
R5	Has_temporal Arg1:T8 Arg2:T13	
R6	AND Arg1:T8 Arg2:T9	
R7	AND Arg1:T23 Arg2:T20	
R8	Subsumes Arg1:T20 Arg2:T17	
R9	Has_qualifier Arg1:T23 Arg2:T22	
R10	Has_negation Arg1:T23 Arg2:T26	
R11	Has_negation Arg1:T27 Arg2:T28	
R12	Has_temporal Arg1:T27 Arg2:T29	
R13	Has_value Arg1:T32 Arg2:T33	
R14	Has_value Arg1:T31 Arg2:T33	
R15	Has_value Arg1:T34 Arg2:T33	
R16	Has_value Arg1:T35 Arg2:T33	
R17	Has_value Arg1:T38 Arg2:T39	
R18	Has_value Arg1:T37 Arg2:T39	
R19	Has_value Arg1:T36 Arg2:T39	
R20	Has_index Arg1:T29 Arg2:T30	
R21	AND Arg1:T23 Arg2:T21	
R22	AND Arg1:T20 Arg2:T21	
R23	AND Arg1:T17 Arg2:T18	
R24	AND Arg1:T18 Arg2:T19	
T1	Condition 0 7	Healthy
T2	Value 14 37	between 18 and 45 years
T3	Person 41 44	age
T4	Measurement 59 74	Body mass index
T5	Value 81 103	between 18 to 30 kg/m2
T6	Qualifier 182 204	clinically significant
T7	Undefined_semantics 182 204	clinically significant
T8	Condition 205 222	abnormal findings
T9	Procedure 226 246	physical examination
T10	Procedure 248 251	ECG
T11	Temporal 253 268	medical history
T12	Procedure 273 292	clinical laboratory
T13	Temporal 301 317	during screening
T14	Negation 179 181	no
T16	Subjective_judgement 338 372	in the opinion of the investigator
T17	Measurement 470 486	serum creatinine
T18	Measurement 488 503	total bilirubin
T19	Measurement 509 528	transaminase levels
T20	Measurement 436 452	hepatic function
T21	Measurement 426 431;444 452	renal function
T22	Qualifier 382 404	clinically significant
T23	Condition 405 422	abnormal findings
T26	Negation 379 381	no
T27	Condition 555 580	users of tobacco products
T28	Negation 551 554	non
T29	Temporal 582 633	minimum of 6 months prior to the start of the study
T30	Reference_point 611 633	the start of the study
T31	Measurement 670 686	screen for HIV I
T32	Measurement 670 684;691 693	screen for HIV II
T33	Value 661 669	negative
T34	Measurement 695 700	HBsAg
T35	Measurement 706 735	antibody to Hepatitis C virus
T36	Measurement 771 795	urine screen for alcohol
T37	Measurement 771 787;797 811	urine screen for drugs of abuse
T38	Measurement 771 787;834 842	urine screen for cotinine
T39	Value 762 770	negative
T40	Post-eligibility 845 1152	Subjects were to use an appropriate barrier method of contraception (condom and spermicide) in addition to having their female partner use another form of barrier contraception (e.g.female condom or occlusive cap with spermicide) during the study and for 3 months following administration of the study drug.
T41	Post-eligibility 1154 1246	Subjects were able to comply with the protocol and the restrictions and assessments therein.
T42	Post-eligibility 1248 1332	Subjects were to give voluntary written informed consent to participate in the trial
